npj Parkinsons Disease

Article	Citations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease	292
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	173
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network	136
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	125
Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson’s disease	124
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	121
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	117
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	113
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	107
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	103
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	101
Differences in brain aging between sexes in Parkinson’s disease	97
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	96
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	90
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	90
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	88
Biological aging predicts mortality in Parkinson’s patients: evidence from UK Biobank	84
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	84
Physiotherapy interventions for balance impairments in Parkinson’s disease: evidence from a systematic review and dose-response meta-analysis	81
Subthalamic nucleus in patients with Parkinson’s disease encodes changes and magnitude of applied force	80
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	78
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	78
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	77
Advanced brain aging in Parkinson’s disease with cognitive impairment	76
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	75

The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model	70
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	69
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	69
Machine learning prediction of discharge destination in patients with Parkinson’s disease; a nationwide cohort study	69
Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease	69
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	64
Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments	64
Video-based machine learning models for predicting deep brain stimulation outcomes in Parkinson’s disease patients	62
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	60
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	60
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	59
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	58
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide	58
The pattern of fMRI activation with STN DBS reveals symptom-specific networks	58
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	57
The experience of Anxiety for people with Parkinson’s disease	57
Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease	56
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease	56
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia	54
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis	54
Enrichment of gut-derived metabolites in a Parkinson’s disease subtype with REM sleep behavior disorder	53
Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder	53
Synuclein phosphorylation: pathogenic or physiologic?	53
Resting and action tremor in Parkinson’s disease: pathophysiological insights from long-term STN-DBS	52
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain	52
Antiviral innate immunity induces alpha synuclein phosphorylation at serine129 in neurons independent of aggregation	52
JNK3 quantification in plasma: a novel biomarker for neuronal damage in Parkinson’s disease	50
Immunological shifts during early-stage Parkinson’s disease identified with DNA methylation data on longitudinally collected blood samples	50
Mapping the developmental path for Parkinson’s disease therapeutics	49
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	47
Optimizing the MDS-UPDRS Part III for early-stage Parkinson’s: early supportive evidence for a limb-related bradykinesia/rigidity sub-score	46
In memorium, Michael Zigmond, PhD	46
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis	45
Single-cell analysis of the peripheral immune landscape in Parkinson’s disease: insights into dendritic cell and CD4+ T-cell transcriptomics	45
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	44
Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease	44
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	44
Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies	43
Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality	43
Inhibition of T cell infiltration and soluble TNF signaling is neuroprotective in the alpha-synuclein overexpressing mouse model of Parkinson’s disease	43
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease	42
Butyrate improves abnormal sleep architecture in a Parkinson’s disease mouse model via BDNF/TrkB signaling	41
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease	41
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease	41
A systematic review and meta-analysis of the prevalence of Parkinson’s disease in lower to upper-middle-income countries	41
Mechanisms of peripheral levodopa resistance in Parkinson’s disease	40
A skin-specific α-Synuclein seeding amplification assay for diagnosing Parkinson’s disease	40
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway	39
Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?	39
Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism	38

Park7 deletion leads to sex-specific transcriptome changes involving NRF2-CYP1B1 axis in mouse midbrain astrocytes	37
Increased frontal [123I]FP-CIT binding in Parkinson’s disease patients with self-reported REM sleep behavior disorder	37
Elevated levels of colonic interleukin-1beta and interleukin-8 in isolated REM sleep behavior disorder without associated changes in permeability	37
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation	37
Parkinson’s disease clinical milestones and mortality	37
Personality profile and its association with conversion to neurodegenerative disorders in idiopathic REM sleep behavior disorder	35
A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic	35
Oral health implications in Parkinson’s disease	35
Digital phenotyping of Parkinson’s disease via natural language processing	35
Brain-region-specific lipid dysregulation in L-DOPA-induced dyskinesia in a primate model of Parkinson’s disease	35
Transcranial static magnetic field stimulation of the primary motor cortex in essential tremor: a randomized pilot study	34
Proceedings of the world summit on parkinson’s disease	34
Analysis of striatal connectivity corresponding to striosomes and matrix in de novo Parkinson’s disease and isolated REM behavior disorder	34
Longitudinal multi-omics in alpha-synuclein Drosophila model discriminates disease- from age-associated pathologies in Parkinson’s disease	34
Efficacy of deep brain stimulation of the subthalamic nucleus versus globus pallidus internus on sensory complaints	33
Associations of digestive diseases exposure and lifestyle factors with Parkinson’s disease	33
Prevalence of low muscle mass and its association with orthostatic hypotension and related symptoms in Parkinson’s disease	33
Modulatory effect of levodopa on the basal ganglia-cerebellum connectivity in Parkinson’s disease	32
Construction of a mild cognitive impairment prediction model for Parkinson’s disease patients on the basis of multimodal data	32
Testing an inverse link between limbic alpha-synucleinopathy and myelin markers in mice and humans	32
MAPKAPK2, a potential dynamic network biomarker of α-synuclein prior to its aggregation in PD patients	32
Peripheral inflammation’s variable impact on cognitive and symptomatic outcomes in Parkinson’s disease: a longitudinal and cross-sectional analysis	32
A framework for translational therapy development in deep brain stimulation	32
Clinical symptoms and neuroanatomical substrates of daytime sleepiness in Parkinson’s disease	32
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers	32
DAT-SPECT-based subtype and stage inference in Parkinson’s disease	31
Hyposmia in Parkinson’s disease; exploring selective odour loss	31
Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson’s disease subtypes	31
TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations	31
Neurophysiological gradient in the Parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy	31
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months	30
Imaging and genome-supported association of glymphatic system function and multiregional brain characteristics with Parkinson’s disease	30
Impaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids	30
Differentiating tremor-dominant parkinson’s disease from essential tremor using neuromelanin- sensitive imaging and T1w/T2w ratio	30
Predictors of stress resilience in Parkinson’s disease and associations with symptom progression	30
Candidate biomarkers of EV-microRNA in detecting REM sleep behavior disorder and Parkinson’s disease	30
STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson’s disease	29
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases	29
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	29
Time to workforce exit after a Parkinson’s disease diagnosis	28
Development of a simplified smell test to identify Parkinson’s disease using multiple cohorts, machine learning and item response theory	28
Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons	28
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)	28
Mendelian randomization reveals association between retinal thickness and non-motor symptoms of Parkinson’s disease	28
PDCD4 triggers α-synuclein accumulation and motor deficits via co-suppressing TFE3 and TFEB translation in a model of Parkinson’s disease	28
Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism	28
Lipid profiling of Parkinson’s disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolism	27
Brain age gap as predictor of disease progression in Parkinson’s disease	27
A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson’s disease	27
Association of glymphatic system function with peripheral inflammation and motor symptoms in Parkinson’s disease	27
Towards scalable screening for the early detection of Parkinson’s disease: validation of an iPad-based eye movement assessment system against a clinical-grade eye tracker	27
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease	27
Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson’s disease	27
AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies	27
Possible role of lncRNAs in amelioration of Parkinson’s disease symptoms by transplantation of dopaminergic cells	27
Sleep disorders in Parkinson’s disease, an early and multiple problem	27
Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease	26
Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson’s disease	26
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease	26
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease	25
Exploring the link between essential tremor and Parkinson’s disease	25
Video-based quantification of hand postural tremor without external references. Integrating postural tremor quantification into visionMD	25
Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study	25
Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease	25
Central biogenic amine deficiency with concomitant exploratory behavioral deficits in Dnajc12 knock-out mice	24
Glutamatergic synaptic resilience to overexpressed human alpha-synuclein	24
Sentence completion in progressive supranuclear palsy following transcranial direct current stimulation	24
Spatial single-cell multiomics reveals peripheral immune dysfunction in Parkinson’s and inflammatory bowel disease	24
Inhibition of de novo ceramide synthesis mitigates alpha-synuclein pathology in a Parkinson’s disease mouse model	24
Data-driven subtyping of early Parkinson’s disease via mutual cross-attention fusion of EEG and dual-task gait features	24
A generalizable and open-source algorithm for real-life monitoring of tremor in Parkinson’s disease	24
Brain-clinical biotyping in patients with idiopathic REM sleep behavior disorder	24
Immune and metabolic signatures characterise constipation-driven endophenotypes in Parkinson’s disease	24
Lack of full sequencing GBA1 studies for patients with Parkinson’s disease in Latin America	24
Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson’s disease patients	24
Genetically-informed prediction of short-term Parkinson’s disease progression	23
Association of wearable sensor-based gait analysis with phenoconversion trajectories in idiopathic REM sleep behavior disorder	23
Microstructural but not macrostructural cortical degeneration occurs in Parkinson’s disease with mild cognitive impairment	23
A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease	23
Modified version of unified multiple system atrophy rating scale for remote video-based assessments	23

Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease	23
Clinical subtypes in patients with isolated REM sleep behaviour disorder	23
Genome-wide association study of copy number variations in Parkinson’s disease	23
Self-perceived life course sleep duration trajectories and risk and age at onset of Parkinson’s disease	23
EEG alpha peak frequency: cognitive impairment severity marker in isolated REM sleep behavior disorder	23
Misfolded protein deposits in Parkinson’s disease and Parkinson’s disease-related cognitive impairment, a [11C]PBB3 study	23
A spatiotemporal hypergraph self-attention neural networks framework for the identification and pharmacological efficacy assessment of Parkinson’s disease motor symptoms	23
α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies	23
Structural underpinnings and long-term effects of resilience in Parkinson’s disease	23
Intracellular α-synuclein assemblies are sufficient to alter nanoscale diffusion in the striatal extracellular space	22
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease	22
Synaptic vesicle characterization of iPSC-derived dopaminergic neurons provides insight into distinct secretory vesicle pools	22
Spatial variations and precise location of substantia nigra hyperechogenicity in Parkinson’s disease using TCS-MR fusion imaging	22
Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination	22
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies	22
Neuropathology of Parkinson’s disease after focused ultrasound thalamotomy	22
The effect of pallidal stimulation on sleep outcomes and related brain connectometries in Parkinson’s disease	22
Author Correction: Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	22
Subthalamic nucleus input-output dynamics are correlated with Parkinson’s burden and treatment efficacy	22
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease	21
Prospective controlled study on the effects of deep brain stimulation on driving in Parkinson’s disease	21
A systematic review of brain morphometry related to deep brain stimulation outcome in Parkinson’s disease	21
Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2	21
Using former carers’ expertise in peer support for carers of people with Parkinson’s Disease	21
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease	21
Different effect of hypo- and hypermetabolism on cognition in dementia with Lewy bodies: are they coupled or independent?	21
Subthalamic nucleus deep brain stimulation alleviates oxidative stress via mitophagy in Parkinson’s disease	21
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice	21
Advancements in invasive and non-invasive neuromodulation for Parkinson’s disease: current findings and future directions	20
Pallidal beta power is associated with depression in Parkinson’s disease	20
Metagenomics indicates an interplay of the microbiome and functional pathways in Parkinson’s disease	20
Prevalence of experienced changes in artistic and everyday creativity in people with Parkinson’s disease	20
Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits	20
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease	20
Neurocognitive correlates of semantic memory navigation in Parkinson’s disease	20
Comprehensive real time remote monitoring for Parkinson’s disease using Quantitative DigitoGraphy	20
Population fraction of Parkinson’s disease attributable to preventable risk factors	20
Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein	20
Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson’s disease	20
Social isolation and the risk of Parkinson disease in the UK biobank study	19
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei	19
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies	19
MRI subtypes in Parkinson’s disease across diverse populations and clustering approaches	19
StimVision: smartphone video kinematics to optimize DBS programming in Parkinson’s disease	19
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease	19
Transcranial direct current stimulation for Parkinson’s disease: systematic review and meta-analysis of motor and cognitive effects	19
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	19
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients	19
Exploring glymphatic system alterations in iRBD and Parkinson’s disease using automated DTI-ALPS analysis	19
AccessPD as a next generation registry to accelerate Parkinson’s disease research	19
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity	19
Modulation of subthalamic beta oscillations by movement, dopamine, and deep brain stimulation in Parkinson’s disease	19
Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson’s disease	19
Altered wakeful theta activity characterizes levodopa-induced dyskinesia in Parkinson’s disease	19
Inherent variability limits clinical utility of reproducible Parkinson’s transcriptomics signatures	18
Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition	18
High-resolution mapping of substantia nigra in Parkinson’s disease using 7 tesla magnetic resonance imaging	18
Towards a methodological uniformization of environmental risk studies in Parkinson’s disease	18
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies	18
Baseline cerebral structural morphology predict freezing of gait in early drug-naïve Parkinson’s disease	18
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease	18
Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation	18
Cerebral perfusion imaging predicts levodopa-induced dyskinesia in Parkinsonian rat model	18
Multi-omic insight into the molecular mechanism of cuproptosis-related genes in the pathogenesis of Parkinson’s disease	17
Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review	17
Deep brain stimulation rectifies the noisy cortex and irresponsive subthalamus to improve parkinsonian locomotor activities	17
Genetic analyses identify circulating genes related to brain structures associated with Parkinson’s disease	17
A single centre prospective study of three device-assisted therapies for Parkinson’s disease	17
Perivascular spread of CSF-derived α-synuclein oligomers drives region-specific Parkinson’s-like pathology	17
Prominent role of PM10 in the link between air pollution and incident Parkinson’s Disease	17
L-Dopa-modified microtubules lead to synapse instability in cultured neurons: possible implications in Parkinson’s disease therapy	17
Optimizing Parkinson’s disease progression scales using computational methods	17
Different risks of early-onset and late-onset Parkinson disease in individuals with mental illness	17
The barriers to receiving health care for people with Parkinson’s from predominantly Asian backgrounds in the UK	17
Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease	17
Effects of deep brain stimulation frequency on eye movements and cognitive control	17
Author Correction: The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data	17
Atrophy of ventral diencephalon is associated with freezing of gait in Parkinson’s disease: analysis of two cohorts	17
Lysosomal genes contribute to Parkinson’s disease near agriculture with high intensity pesticide use	16
Strain-specific effects of Desulfovibrio on neurodegeneration and oxidative stress in a Caenorhabditis elegans PD model	16
Single-cell RNA sequencing reveals peripheral immunological features in Parkinson’s Disease	16
Circulating blood circular RNA in Parkinson’s Disease; from involvement in pathology to diagnostic tools in at-risk individuals	16
Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD	16
Synthetic MRI study of brain volume and subcortical myelin in various Parkinson’s disease motor subtypes	16
Electrophysiological approaches to informing therapeutic interventions with deep brain stimulation	16
Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis	16
Accelerating Parkinson’s Disease drug development with federated learning approaches	16
Wearable-sensor based walking and non-walking measures as progression markers in early to mid-stage Parkinson’s disease	16
Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson’s disease	16
Regional-specific structural and functional changes of posterior cerebellar vermis across different stages of Parkinson’s disease with gait dysfunction	16
Clinico-physiological correlates of Parkinson’s disease from multi-resolution basal ganglia recordings	16
Subthalamic beta bursts correlate with dopamine-dependent motor symptoms in 106 Parkinson’s patients	16
Disease progression strikingly differs in research and real-world Parkinson’s populations	16
Modulation of DBS-induced cortical responses and movement by the directionality and magnitude of current administered	16
GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate	16